The following article has been retracted at the request of the Editor and Publisher:
Folk A, Balta C, Herman H, et al. Flucytosine and Amphotericin B Coadministration Induces Dose-Related Renal Injury. Dose-Response. 2017;15(2). doi: 10.1177/1559325817703461
• Fig. 4(I) shows partial overlap between Panels A (control) and B (treatment).
The authors provided the raw images for Figure 4 and requested to replace Fig. 4 (I) Panel A. The journal editor and Sage reviewed the request and the raw images and deemed that concerns regarding image integrity were present.
Due to the unresolved concerns about image integrity, that call into question the validity of the findings, the Journal Editor and Sage retract the article.
Author Hermenean A did not agree with the retraction. Authors Ardelean A could not be reached. Other authors did not comment.
References
1.
ZaragozaRPemanJSalavertM. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?Ther Clin Risk Manag. 2008;4(6):1261–1280.
VermesAGuchelaarHJDankertJ. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171–179.
13.
FolkACotoraciCBaltaC. Evaluation of hepatotoxicity with treatment doses of flucytosine and amphotericin B for invasive fungal infections. BioMed Res Int. 2016;2016:5398730. doi:10.1155/2016/5398730.
14.
SoltaniMTobinCMBowkerKESunderlandJMacGowanAPLoveringAM. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents. 2006;28(6):574–577.
15.
SchwarzPDromerFLortholaryODannaouiE. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother. 2006;50(
1
):113–120.
16.
LivakKJSchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 ΔΔ C(T) method. Method. 2001;25(4):402–408.
17.
FergusonMAVaidyaVSBonventreJV. Biomarkers of nephrotoxic acute kidney injury. Toxicology. 2008;245(3):182–193.
18.
BenedettiGRamaiahgarisSHerpersBvan de WaterBPriceLSde GraauwM. A screen for apoptotic synergism between clinical relevant nephrotoxicant and the cytokine TNF- α. Toxicol In Vitro. 2013;27(8):2264–2272.
19.
AkcayANguyenQEdelsteinCL. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009;2009:137072. doi:10.1155/2009/137072.
20.
LeemanJGilmoreTD. Alternative splicing in the NF-κB signaling pathway. Gene. 2008;423(2):97–107.
21.
DonnahooKKMeldrumDRShenkarRChungCSAbrahamEHarkenAH. Early renal ischemia, with or without reperfusion, activates NFκB and increases TNF-α bioactivity in the kidney. J Urol. 2000;163(4):1328–1332.
SetoMKimSYoshifusaH. Effects of prednisolone on glomerular signal transduction cascades in experimental glomerulonphritis. J Am Soc Nephrol. 1998;9(8):1367–1376.
24.
GaoRChenJHuY. Sirt1 deletion leads to enhanced inflammation and aggravates endotoxin-induced acute kidney injury. PloS One. 2014;9(6): e98909.
25.
GhoshSKarinM. Missing pieces in the NF-kappaB puzzle. Cell. 2002;(suppl 109): S81–S96.
RameshGKimballSRJeffersonLSReevesWB. Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells. Am J Physiol Renal Physiol. 2007;292(2): F812–F819.
28.
LiuMChienCCBurne-TaneyM. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol. 2006;17(3):765–774.
29.
PiaoRLLiuYYTianD. Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in patients with chronic hepatitis B. Mol Med Rep. 2012;5(1):184–189.
30.
AsvadiIHajipourBAsvadiAAslNARoshangarLKhodadadiA. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur Rev Med Pharmacol Sci. 2011;15(9):1003–1009.
31.
PogrebniakHWMatthewsWPassHI. Chemotherapy amplifies production of tumor necrosis factor. Surgery. 1991;110(2):231–237.
32.
DuSHiramatsuNHayakawaK. Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/ EBP family: implication for unfolded protein response. J Immunol. 2009;182(11):7201–7211.
33.
VarlamDESiddiqMMPartonLARussmannH. Apoptosis contributes to amphotericin B induced nephrotoxicity. Antimicrob Agents Chemother. 2001;45(
3
):679–685.
34.
BolardJ. How do the polyene macrolide antibiotics affect the cellular membrane properties?Biochim Biophys Acta. 1986;864(
3-4
):257–304.
35.
ChengJTWittyRTRobinsonRRYargerWE. Amphotericin B nephrotoxicity: increased renal resistance and tubule permeability. Kidney Int. 1982;22(6):626–633.
36.
BurgessJLBirchallR. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med. 1972;53(1):77–84.
37.
BottingerEPBitzerM. TGF-beta signaling in renal disease. J. Am. Soc. Nephrol. 2002;13(10):2600–2610.
38.
SchifferMBitzerMRobertsIS. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest. 2001;108(6):807–816.
39.
ChoiMEBallermannBJ. Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. J Biol Chem. 1995;270(36):21144–21150.
40.
YoshikawaMHishikawaKIdeiMFujitaT. Trichostatin a prevents TGF-β1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells. Eur J Pharmacol. 2010;642(1-3):28–36.
41.
RazzaqueMSAhsanNTaguchiT. Role of apoptosis in fibrogenesis. Nephron. 2002;90(4):365–372. doi:10.1159/000054722.
42.
ZeisbergMBonnerGMaeshimaY. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol. 2001;159(
4
):1313–1321.
43.
ZeisbergMKalluriR. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl). 2004;82(3):175–181.
MeldrumKKMisseriRMetcalfePDinarelloCAHileKLMeldrumDR. TNF-alpha neutralization ameliorates obstruction-nduced renal fibrosis and dysfunction. Am J Physiol Regul Integr Comp Physiol. 2007;292(4): R1456–R1464.
46.
FogoAB. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol. 2007;22(12):2011–2022.
47.
WanYGCheXYSunW. Low-dose of multi-glycoside of Tripterygium wilfordii Hook.f., a natural regulator of TGF-β1/Smad signaling activity improves adriamycin-induced glomerulosclerosis in vivo. J Ethnopharmacol. 2014;151(3):1079–1089. doi:10.1016/j.jep.2013.12.005.
